Pair page
Selank with Semax
Mechanism-tag overlap and published literature for Selank and Semax, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
anxiolytic-nootropictuftsin-analog
acth-analogneuroprotectivenootropic
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying Selank and Semax have published these mechanism-level observations. Not a co-administration recommendation.
The most common Selank stack. Semax is another Russian heptapeptide, ACTH-derived, with complementary cognitive-enhancement and BDNF-elevating mechanism. Alternating Semax (AM) and Selank (PM) is a common bidirectional nootropic/anxiolytic protocol.
The canonical Russian peptide stack. Semax in the AM for cognitive/focus effect; Selank in the PM for stress-resilience/anxiolytic effect. Complementary BDNF-elevating mechanisms with different emotional/cognitive emphasis.
Quick facts
Selank
Semax
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2008 | Selank | Zozulia AA, Neznamov GG, Syunyakov TS, et al. [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48. PMID: 18454096. (Russian Phase… PMID 18454096 | human trial, Phase 3 |
| 2015 | Selank | Medvedev VE, Teresh'chenko OE, Israelyan AY, et al. [Optimization of therapy with traditional anxiolytic drugs in patients with anxiety-asthenic disorders]. Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(4):33-40. | human study |
| 2008 | Selank | Uchakina ON, Uchakin PN, Miasoedov NF, et al. [Immunomodulatory effects of selank in patients with anxiety-asthenic disorders]. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(5):71-75. | human study |
| 2019 | Selank | Inozemtseva LS, Kudryavtseva NN, Bobkova NV, Dolotov OV, Gerasimova OA, Levitskaya NG, Kamensky AA, Andreeva LA, Myasoedov NF, Grivennikov IA. Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus… PMID 31625062 | preclinical, in vivo |
| 2017 | Selank | Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Biomed Res Int. 2017;2017:2875904. PMC5322660. | preclinical, in vivo |
| 2008 | Selank | Inozemtseva LS, Karpenko EA, Dolotov OV, Levitskaya NG, Kamensky AA, Andreeva LA, Grivennikov IA. Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Dokl Biol Sci. 2008;421:241-243. PMID: 18841778. PMID 18841778 | preclinical, in vivo |
| 2007 | Selank | Semenova TP, Medvinskaia NI, Nesterova IV, Kozlovskaia MM. [Experimental analysis of the effect of Selank on the emotional and cognitive behavior of mice]. Zh Vyssh Nerv Deiat Im I P Pavlova. 2007;57(6):738-743. | preclinical, in vivo |
| 1998 | Selank | Seredenin SB, Kozlovskaia MM, Blednov IuA, Kozlovskii II. [Anxiolytic properties of Selank in BALB/c mice with differences in dopamine system reactivity]. Biull Eksp Biol Med. 1998;126(4):402-406. PMID: 9868709. PMID 9868709 | preclinical, in vivo |
| 2009 | Selank | Russian Federation State Register of Medicines. Selank — 0.15% intranasal solution. Approved 2009. | regulatory / registry |
| 2017 | Selank | Filatova E, Kasian A, Kolomin T, Rybalkina E, Alieva A, Andreeva L, Limborska S, Myasoedov N, Pavlova G, Slominsky P, Shadrina M. GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. Front Pharmacol. 2017;8:89. PMID… PMID 28316569 | research article |
| 2016 | Selank | Volkova A, Shadrina M, Kolomin T, Andreeva L, Limborska S, Myasoedov N, Slominsky P. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Front Pharmacol. 2016;7:31. PMID: 26903861. PMC4757669. PMID 26903861 | research article |
| 2003 | Selank | Kozlovskaya MM, Kozlovskii II, Val'dman EA, Seredenin SB. Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress. Neurosci Behav Physiol. 2003;33(7):639-643. PMID: 14552536. PMID 14552536 | research article |
| 2002 | Semax | Skvortsova VI, Platonova IA, Tvorogova TV, Miasoedov NF. Effect of semax on disability and handicap indexes in patients survived carotid ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2002;102(Suppl 5):36-39. | human study |
| 2020 | Semax | Filippenkov IB, Stavchansky VV, Denisova AE, et al. Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats. Genes (Basel). 2020;11(6):681. | preclinical, in vivo |
| 2013 | Semax | Glazova NY, Sebentsova EA, Manchenko DM, et al. Prolonged beneficial effect of neonatal treatment with Semax on the grooming behavior of elderly rats. Bull Exp Biol Med. 2013;155(6):731-733. | preclinical, in vivo |
| 2011 | Semax | Stavchansky VV, Tvorogova TV, Botsina AY, Skvortsova VI, Limborska SA, Myasoedov NF, Dergunova LV. The effect of Semax and its C-end peptide PGP on expression of neurotrophins and their receptors in rat brain during incomplete global ischemia. Mol Biol (Mosk). 2011;45(6):1026-10… | preclinical, in vivo |
| 2010 | Semax | Shadrina M, Kolomin T, Agapova T, et al. Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action. J Mol Neurosci. 2010;41(1):30-35. | preclinical, in vivo |
| 2007 | Semax | Agapova TY, Agniullin YV, Shadrina MI, Shram SI, Slominsky PA, Lymborska SA, Myasoedov NF. Neurotrophin gene expression in rat brain under the action of Semax, an analogue of ACTH(4-10). Neurosci Lett. 2007;417(2):201-205. | preclinical, in vivo |
| 2007 | Semax | Storozheva ZI, Proshin AT, Sherstnev VV, Stolyarov ID, Boĭko AN. Effects of Semax on different forms of learning and memory in adult and aged rats. Bull Exp Biol Med. 2007;143(4):482-485. | preclinical, in vivo |
| 2006 | Semax | Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. J Neurochem. 2006;97 Suppl 1:82-86. PMID: 16635254. PMID 16635254 | preclinical, in vivo |
| 2006 | Semax | Volkova MV, Shadrina MI, Kolomin TA, Dolotov OV, Grivennikov IA, Shaburova EV, Solntseva OS, Myasoedov NF, Limborska SA, Slominsky PA. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006;1117(1):54-60.… PMID 16996037 | preclinical, in vivo |
| 1991 | Semax | Potaman VN, Antonova LV, Dubynin VA, et al. Entry of the synthetic ACTH(4-10) analogue into the rat brain following intravenous injection. Neurosci Lett. 1991;130(1):11-13. | preclinical, in vivo |
| 1997 | Semax | Gusev EI, Skvortsova VI, Miasoedov NF, Nezavibatko VN, Zhuravleva EIu, Vanichkin AV. [Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)]. Zh Nevrol Psikhiatr Im S S Korsakova. 1997;97(6):26-34. PMID: 11517472. PMID 11517472 | research article |
Related pair pages
More research context
Frequently asked
Have Selank and Semax been studied together?
Researchers have published mechanistic-level co-administration discussion of Selank and Semax. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do Selank and Semax share?
Selank and Semax do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of Selank and Semax?
Selank: Not approved. Semax: Not approved. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Selank and Semax?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Selank profile and the Semax profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026